Equities
  • Price (EUR)62.20
  • Today's Change-0.20 / -0.32%
  • Shares traded1.00
  • 1 Year change-39.02%
  • Beta0.6781
Data delayed at least 15 minutes, as of Feb 11 2026 08:22 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.

  • Revenue in USD (TTM)20.08bn
  • Net income in USD2.90bn
  • Incorporated1979
  • Employees53.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BSX:NYQ since
announced
Transaction
value
Penumbra IncAnnounced15 Jan 202615 Jan 2026Announced-20.81%15.05bn
Valencia Technologies CorpDeal completed12 Jan 202612 Jan 2026Deal completed-23.98%--
Nalu Medical IncAnnounced17 Oct 202517 Oct 2025Announced-24.08%533.00m
Elutia Inc-BioEnvelope BusinessDeal completed09 Sep 202509 Sep 2025Deal completed-31.36%88.00m
SoniVie LtdDeal completed03 Mar 202503 Mar 2025Deal completed-28.48%540.00m
Data delayed at least 15 minutes, as of Feb 11 2026 16:43 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.